Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for banking industry professionals · Wednesday, August 21, 2019 · 494,167,677 Articles · 3+ Million Readers

Aurora-GT (Endothelial Nitric Oxide-Synthase-Enhanced Endothelial Progenitor Cells) Drug Overview

/EIN News/ -- Dublin, July 16, 2019 (GLOBE NEWSWIRE) -- The "Aurora-GT" report has been added to's offering.

United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells), which is intended to rebuild blood vessels in the lung. Administering this gene therapy involves isolating a PAH patient's autologous endothelial progenitor cells, transfecting the cells with the gene for human endothelial NO-synthase, prior to their ex-vivo expansion, and reintroducing them into the same patient.

Analyst Outlook

United Therapeutics is aiming to diversify its pulmonary hypertension (PH) portfolio with a pipeline gene therapy product, Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells). The company stands out as the only one with a late-phase gene therapy in development. If successful, this therapy could address critical unmet need in the PH market for options beyond symptomatic treatment. The author awaits further developments for Aurora-GT, as Phase II/III clinical trial data are yet to be released.

Key Topics Covered:


  • Drug Overview
  • Product Profiles
  • Aurora-GT : Pulmonary hypertension

Figure 1: Aurora-GT for pulmonary hypertension - SWOT analysis

Table 1: Aurora-GT drug profile
Table 2: Aurora-GT Phase II trial in pulmonary hypertension

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Respiratory Drugs


Powered by EIN News

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release